Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Elias E. Letsios
Observed names:
E Letsios,
Elias Letsios
Observed institutions:
Lahey Hospital and Medical Center,
Cleveland Clinic,
Mayo Clinic,
Henry Ford Health,
Rhode Island Hospital
OpenAlex ID:
A5033992968
A Noninvasive Blood-based Combinatorial Proteomic Biomarker Assay to Detect Breast Cancer in Women Under the Age of 50 Years
2017
·
Ana P. Lourenco
, Kasey L. Benson
, et al.
·
Clinical Breast Cancer
·
31
Integration of Serum Protein Biomarker and Tumor Associated Autoantibody Expression Data Increases the Ability of a Blood-Based Proteomic Assay to Identify Breast Cancer
2016
·
Meredith C. Henderson
, Alan B. Hollingsworth
, et al.
·
PLoS ONE
·
31
PDF
A Noninvasive Blood-based Combinatorial Proteomic Biomarker Assay to Detect Breast Cancer in Women over age 50 with BI-RADS 3, 4, or 5 Assessment
2018
·
Meredith C. Henderson
, Michael Silver
, et al.
·
Clinical Cancer Research
·
29
Breast density does not impact the ability of Videssa® Breast to detect breast cancer in women under age 50
2017
·
David E. Reese
, Meredith C. Henderson
, et al.
·
PLoS ONE
·
7
PDF
Abstract P6-03-03: Not presented
2018
·
MC Henderson
, M Silver
, et al.
·
Cancer Research
·
2
A Combinatorial Proteomic Biomarker Assay to Detect Ovarian Cancer in Women
2018
·
Meredith C Henderson
, Michael Silver
, et al.
·
Biomarkers in Cancer
·
2
Supplementary Tables from A Noninvasive Blood-based Combinatorial Proteomic Biomarker Assay to Detect Breast Cancer in Women over age 50 with BI-RADS 3, 4, or 5 Assessment
2023
·
Meredith C. Henderson
, Michael Silver
, et al.
Figure S4 from A Noninvasive Blood-based Combinatorial Proteomic Biomarker Assay to Detect Breast Cancer in Women over age 50 with BI-RADS 3, 4, or 5 Assessment
2023
·
Meredith C. Henderson
, Michael Silver
, et al.
Figure S2 from A Noninvasive Blood-based Combinatorial Proteomic Biomarker Assay to Detect Breast Cancer in Women over age 50 with BI-RADS 3, 4, or 5 Assessment
2023
·
Meredith C. Henderson
, Michael Silver
, et al.
Figure S1 from A Noninvasive Blood-based Combinatorial Proteomic Biomarker Assay to Detect Breast Cancer in Women over age 50 with BI-RADS 3, 4, or 5 Assessment
2023
·
Meredith C. Henderson
, Michael Silver
, et al.
Figure S5 from A Noninvasive Blood-based Combinatorial Proteomic Biomarker Assay to Detect Breast Cancer in Women over age 50 with BI-RADS 3, 4, or 5 Assessment
2023
·
Meredith C. Henderson
, Michael Silver
, et al.
Figure S3 from A Noninvasive Blood-based Combinatorial Proteomic Biomarker Assay to Detect Breast Cancer in Women over age 50 with BI-RADS 3, 4, or 5 Assessment
2023
·
Meredith C. Henderson
, Michael Silver
, et al.
Supplementary Tables from A Noninvasive Blood-based Combinatorial Proteomic Biomarker Assay to Detect Breast Cancer in Women over age 50 with BI-RADS 3, 4, or 5 Assessment
2023
·
Meredith C. Henderson
, Michael Silver
, et al.
PDF
Figure S4 from A Noninvasive Blood-based Combinatorial Proteomic Biomarker Assay to Detect Breast Cancer in Women over age 50 with BI-RADS 3, 4, or 5 Assessment
2023
·
Meredith C. Henderson
, Michael Silver
, et al.
Figure S3 from A Noninvasive Blood-based Combinatorial Proteomic Biomarker Assay to Detect Breast Cancer in Women over age 50 with BI-RADS 3, 4, or 5 Assessment
2023
·
Meredith C. Henderson
, Michael Silver
, et al.
Figure S1 from A Noninvasive Blood-based Combinatorial Proteomic Biomarker Assay to Detect Breast Cancer in Women over age 50 with BI-RADS 3, 4, or 5 Assessment
2023
·
Meredith C. Henderson
, Michael Silver
, et al.
Figure S5 from A Noninvasive Blood-based Combinatorial Proteomic Biomarker Assay to Detect Breast Cancer in Women over age 50 with BI-RADS 3, 4, or 5 Assessment
2023
·
Meredith C. Henderson
, Michael Silver
, et al.
Data from A Noninvasive Blood-based Combinatorial Proteomic Biomarker Assay to Detect Breast Cancer in Women over age 50 with BI-RADS 3, 4, or 5 Assessment
2023
·
Meredith C. Henderson
, Michael Silver
, et al.
Data from A Noninvasive Blood-based Combinatorial Proteomic Biomarker Assay to Detect Breast Cancer in Women over age 50 with BI-RADS 3, 4, or 5 Assessment
2023
·
Meredith C. Henderson
, Michael Silver
, et al.
Figure S2 from A Noninvasive Blood-based Combinatorial Proteomic Biomarker Assay to Detect Breast Cancer in Women over age 50 with BI-RADS 3, 4, or 5 Assessment
2023
·
Meredith C. Henderson
, Michael Silver
, et al.
Abstract P4-01-07: A liquid biopsy test for breast cancer detection provides consistent diagnostic results in patients over six months
2017
·
KL Benson
, MC Henderson
, et al.
·
Cancer Research
Abstract P1-02-08: Provista-002: A prospective, multi-center study to determine the effectiveness of a biomarker assay to distinguish benign from invasive breast cancer in women with BI-RADS 3, 4 and 5 imaging reports
2017
·
J Wolf
, A Lourenco
, et al.
·
Cancer Research
Abstract P5-03-03: A blood-based proteomic Videssa® breast assay performs comparably in women with dense and non-dense breasts
2017
·
M Silver
, Q Tran
, et al.
·
Cancer Research
Provista 002 prospective randomized trial utilizing Videssa in conjunction with imaging to detect breast cancer from patients with imaging findings age 25-75.
2015
·
David Emery Reese
, Rao Mulpuri
, et al.
·
Journal of Clinical Oncology
Show more works
View as search
Works count:
24
Citation count:
102
H-index:
4
I10-index:
3
Year
Topic
Type